News

Recent News > SoftVue Acquisitions

Delphinus Announces Installation of Its SoftVue Breast Ultrasound Tomography System at McLeod Regional Medical Center

July 23, 2024

Medical Director Dr. W. Shawn Conwell Says System Will Help Clinicians “Reliably Distinguish Between Dense Tissue, Benign Lesions and Cysts, and Cancers That Can be Lurking Underneath”

NOVI, Mich.--(BUSINESS WIRE)-- Delphinus Medical Technologies, a pioneering medical imaging company that developed the SoftVue™ Breast Ultrasound Tomography (UST), today announced the latest installation of its breakthrough breast imaging technology at McLeod Regional Medical Center, Florence, S.C.

SoftVue UST is the only imaging modality designed specifically to find more cancer in women with dense breasts and is also the only ultrasound-based breast imaging system that is FDA-approved for same-day screening as mammography. Delphinus designed the system as an adjunct to mammography for women with dense breasts to address the fact that breast cancer screening with mammography alone reduces mortality by 41% in women with non-dense breasts but reduces mortality by only 13% in women with dense breasts.

“Mammogram screening has been plagued for decades by the challenges of breast tissue density,” said W. Shawn Conwell, MD, FACR, medical director, Breast and Women’s Imaging, McLeod Regional Medical Center. “The denser the breast tissue, the harder it is to detect a mass. It’s like looking for a polar bear in a snowstorm.”

When combined with mammography, SoftVue increases sensitivity by 20 percent and specificity by eight percent, offering comprehensive characterization at the point of screening which helps increase cancer detection and reduce short-term follow-ups.

According to Dr. Conwell, “SoftVue allows whole breast ultrasound tomography to be performed in a controlled, reproducible setting. Because the entire breast is imaged and archived, we can compare with prior exams and detect changes over time. Moreover, SoftVue is an advancement over standard ultrasound because it goes beyond typically-used grayscale, offering images that contain additional important data that can be overlayed upon each other to create a complex tissue character map of the breast. Using this technology, we can reliably distinguish between dense tissue, benign lesions and cysts, and cancers that may be lurking underneath.”

“McLeod Regional Medical Center is one of a growing number of healthcare institutions that recognize the need to dramatically improve the standard of care for women with dense breasts and are adopting SoftVue as the solution,” said Scott White, CEO of Delphinus Medical Technologies. “We are proud to partner with the McLeod team to bring the advantages of SoftVue to women of the south region who are served by this forward-looking organization.”